Yesterday the company terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.
Tag Archive for: Amgen
The drug was being studied for the treatment of Immunoglobulin G4-related disease, which is characterized by periods of remission and unpredictable disease flares.
There are several other drug developers aiming to join the weight loss drug bandwagon. The following is a list of publicly listed companies targeting the next big blockbuster opportunity.
Yesterday Amgen secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two rare diseases.
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
The drug, marketed under the name Imdelltra, is part of Amgen’s pipeline of bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body’s immune system can kill the cancer.
Following strong Phase II data, Amgen is going all in on its next-generation obesity treatment MariTide, with plans to run a Phase III trial and a separate mid-stage study for diabetes.
Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday.
Bristol Myers Squibb’s $4.8 billion acquisition of Mirati pays off with strong data from the KRYSTAL-12 study of Krazati, showing that the KRAS inhibitor significantly improves progression-free survival.
Sandoz’s Jubbonti will challenge Amgen’s Prolia for the treatment of osteoporotic men and postmenopausal women who are at high risk of fracture. Like its branded reference product, the biosimilar is also indicated for glucocorticoid-induced osteoporosis.